Effects of ramipril and darbepoetin on electromechanical activity of the heart in doxorubicin-induced cardiotoxicity.

[1]  A. Connolly,et al.  Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function. , 2011, The Journal of thoracic and cardiovascular surgery.

[2]  O. Garrone,et al.  Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. , 2011, International journal of cardiology.

[3]  Kyoung-Han Kim,et al.  Erythropoietin Protects against Doxorubicin-Induced Cardiomyopathy via a Phosphatidylinositol 3-Kinase-Dependent Pathway , 2008, Journal of Pharmacology and Experimental Therapeutics.

[4]  Y. Arbel,et al.  QT prolongation and Torsades de Pointes in patients previously treated with Anthracyclines , 2007, Anti-cancer drugs.

[5]  T. Fujita,et al.  Efficacy of Darbepoetin in Doxorubicin-Induced Cardiorenal Injury in Rats , 2006, Nephron Experimental Nephrology.

[6]  Y. Nishijima,et al.  Acute effects of tacrolimus (FK506) on left ventricular mechanics. , 2005, Pharmacological research.

[7]  J. Cleland,et al.  Clinical trials update from the European Society of Cardiology Heart Failure meeting and the American College of Cardiology: Darbepoetin alfa study, ECHOS, and ASCOT‐BPLA , 2005, European journal of heart failure.

[8]  L. Gianni,et al.  Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.

[9]  D. Silverberg,et al.  The cardio-renal anaemia syndrome: does it exist? , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  D. Bicket.  Using ACE inhibitors appropriately. , 2002, American family physician.